2020 Oncology Drug Coding and Updates

The COVID-19 pandemic has transformed healthcare delivery around the world, including the treatment of patients with cancer. As providers and administrators strive to create and implement new procedures to protect their staff and patients from the virus, it is equally important that they continue established protocols that are critical to the effective management of their practices during these unprecedented times. With this goal in mind, we are pleased to present this 2020 Oncology Drug Coding and Updates special feature, designed to provide you with important information on the topic of oncology drug coding and details on some of the newest drugs available to treat patients with cancer. Read More ›

These detailed tables of codes and pricing related to drugs used to treat breast cancer, lung cancer, gynecologic malignancies, and hematologic malignancies are intended to assist practice managers, other healthcare providers, and payers to ensure the proper use of coding and billing information associated with the treatment of their patients. Read More ›

Diffuse large B-cell lymphoma (DLBCL) is one of the most common types of non-Hodgkin lymphoma and the most common blood cancer. DLBCL accounts for approximately 33% of all lymphomas. DLBCL is an aggressive cancer that may start in the lymph nodes or outside the lymphatic system and may affect the bone, bone marrow, gastrointestinal tract, brain, breast, testes, liver, spleen, or other organs. Read More ›

Cholangiocarcinoma (CCA), a group of heterogeneous cancers that originate in the bile ducts that connect the liver and gallbladder to the small intestine, affects 2000 to 3000 individuals annually in the United States. The disease most often affects older people aged ≥65 years and occurs slightly more frequently in men than in women. Read More ›

Urothelial carcinoma, also known as transitional-cell carcinoma (TCC), is the most common subtype of bladder cancer. Based on data from 2016, more than 80,000 cases of bladder cancer were estimated to be diagnosed in the United States in 2019, and approximately 17,600 patients were expected to die from this disease. Read More ›

Breast cancer is the most prevalent cancer in women in the United States, accounting for 15.3% of all new cancer cases. In 2020 alone, 276,480 women are estimated to be diagnosed with breast cancer and an estimated 42,170 women will die from this disease. Overall, the 5-year relative survival rate for women with breast cancer is 90%; however, the 5-year survival rate drops to 28.1% for patients with metastatic disease. Read More ›